Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) announced that the first patient was dosed in December 2025 for its global Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE